创模生物科技(北京)有限公司

CN / En

NEWS

Features of the IC50 platform from InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-02-06 10:22
  • Views:

(Summary description)InnoModels Biotechnology has always been committed to advancing the innovation and development of biotechnology, and its IC50 platform is one of the key technological achievements that the company is proud of. This platform plays a key role in drug screening and toxicity assessment, providing scientists with efficient and reliable tools to accelerate the process of new drug development.

Features of the IC50 platform from InnoModels Biotechnology

(Summary description)InnoModels Biotechnology has always been committed to advancing the innovation and development of biotechnology, and its IC50 platform is one of the key technological achievements that the company is proud of. This platform plays a key role in drug screening and toxicity assessment, providing scientists with efficient and reliable tools to accelerate the process of new drug development.

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-02-06 10:22
  • Views:
Information

InnoModels Biotechnology has always been committed to advancing the innovation and development of biotechnology, and its IC50 platform is one of the key technological achievements that the company is proud of. This platform plays a key role in drug screening and toxicity assessment, providing scientists with efficient and reliable tools to accelerate the process of new drug development.
Efficient drug screening tool
The IC50 platform is an efficient drug screening tool developed by InnoModels Biotechnology. Through this platform, scientists are able to quickly assess the inhibitory ability of a drug candidate on a specific cell line, and thus determine its efficacy in an in vitro environment. This high-throughput screening method greatly shortens the drug development cycle and provides an objective basis for the superiority of drug candidates.
Diverse Cell Line Selection
The IC50 platform supports a diverse selection of cell lines to meet the needs of different research fields and drug development stages. Whether it is tumor cell lines, primary cells, or transgenic cell lines, IC50 platform can provide corresponding experimental models, providing scientists with a research platform that is closer to the actual situation.
Accurate Toxicity Assessment
In addition to drug screening, the IC50 platform can also be used for accurate toxicity assessment. Scientists can use the platform to determine the half inhibitory concentration (IC50 value) of a drug to assess its safety and toxicity profile. This precise toxicity assessment helps to identify potential drug toxicity problems early and reduces risks during drug development.

 


Flexible Experiment Design and Data Analysis
InnoModels's IC50 platform not only provides flexible experimental design, but also equipped with advanced data analysis tools. Scientists can freely choose experimental parameters and customize experimental protocols according to their experimental needs. At the same time, the IC50 platform also provides a variety of data analysis models and algorithms to help scientists accurately and comprehensively interpret the experimental results, thus guiding the subsequent research and development work.
Continuous Technology Optimization and Customer Support
InnoModels Biotechnology is committed to continuously optimizing the technical performance of the IC50 platform and providing a full range of customer support services. Whether it is technical training, experimental guidance, or after-sales service, the company is committed to customer satisfaction and ensuring that users can fully utilize the advantages of the IC50 platform for scientific research and drug development.
Summary
InnoModels's IC50 platform is well known in the industry for its highly efficient drug screening tools, diverse selection of cell lines, accurate toxicity assessment, flexible experimental design and data analysis, as well as continuous technical optimization and customer support. This platform provides scientists with powerful tools to accelerate the process of drug discovery and development, driving innovation and development in the biotechnology field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司